摘要
该研究运用海马体成分表征及网络药理学等方法,探讨丹栀逍遥方在相关神经疾病中的药效成分和潜在药理学功能。对大鼠进行丹栀逍遥方灌胃给药后,采用高效液相色谱-四极杆飞行时间质谱联用技术(HPLC-Q-TOF-MS/MS)探究其海马体内成分,通过对比复方提取物、给药后海马体复方成分及空白样本,在大鼠海马体中发现了57个成分。经网络药理学分析确定了GSK3B、MAPK1、AKT、IL6等74个核心靶点,这些靶点参与PI3K/Akt、NF-κB、MAPK、JAK/STAT、Wnt等信号通路。研究结果表明,丹栀逍遥方对DO富集的神经退行性疾病、脑血管疾病、精神与情绪障碍等其他神经系统疾病可能通过介导靶点通路,抑制炎症反应,减少神经元损伤,缓解海马体萎缩等机制,发挥干预作用。该方在阿尔茨海默病、帕金森病、糖尿病神经病变等神经系统疾病方面展现出的相关活性具有较高的开发价值,值得进一步深入研究,从而为拓展丹栀逍遥方在神经系统疾病治疗领域的应用提供理论依据与实践指导。
In this study,the pharmacodynamic components and potential pharmacological functions of Danzhi Xiaoyao Formula in treating nervous system diseases were investigated by hippocampal component characterization and network pharmacology.After rats were administrated with Danzhi Xiaoyao Formula by gavage,high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry(HPLC-Q-TOF-MS/MS)was employed to explore the components in the hippocampus of rats.Fifty-seven components were identified in the hippocampus of rats by comparing the extract of Danzhi Xiaoyao Formula,herbal components in the hippocampus after administration,and blank samples.KEGG and GO analyses predicted 74 core targets including GSK3B,MAPK1,AKT,IL6.These targets were involved in PI3K/Akt,NF-κB,MAPK,JAK/STAT,Wnt,and other signaling pathways.The results indicated that Danzhi Xiaoyao Formula may ameliorate other nervous system diseases enriched in DO,such as neurodegenerative diseases,cerebrovascular diseases,and mental and emotional disorders by mediating target pathways,inhibiting inflammation,reducing neuronal damage,and alleviating hippocampal atrophy.The relevant activities exhibited by this formula in nervous system diseases such as Alzheimer′s disease,Parkinson′s disease,and diabetic neuropathy have extremely high development value and are worthy of further in-depth research.This study provides a theoretical basis and practical guidance for expanding the application of Danzhi Xiaoyao Formula in the treatment of nervous system diseases.
作者
胡文青
高慧媛
杨丽
王榆鑫
程浩洁
杨司宇
张美玉
孙健
HU Wen-qing;GAO Hui-yuan;YANG Li;WANG Yu-xin;CHENG Hao-jie;YANG Si-yu;ZHANG Mei-yu;SUN Jian(School of Traditional Chinese Materia Medica,Shenyang Pharmaceutical University,Benxi 117004,China;Experimental Research Center,China Academy of Chinese Medical Sciences,Bejing 100700,China;Heilongjiang University of Chinese Medicine,Harbin 150040,China)
出处
《中国中药杂志》
北大核心
2025年第14期4053-4062,共10页
China Journal of Chinese Materia Medica
基金
中央级公益性科研院所基本科研业务费专项(JJPY2023001)
中国中医科学院科技创新工程中医药实验能力提升专项(NLTS2025007)
国家自然科学基金项目(81603491)。
